Full Press Release Details
Vesting of awards under the Long Term Incentive Plan
London: Monday, March 9, 2020: Hutchison China MediTech Limited ( Chi-Med ) (Nasdaq/AIM: HCM) announces that following the announcement of the 2019 annual results of Chi-Med on March 3, 2020, the following awards granted under the Long Term Incentive Plan ( LTIP ) on March 15, 2017 to Mr Christian Hogg, Mr Johnny Cheng and Dr Weiguo Su were vested on March 6, 2020:-
| Award Holders | Number of American depositary shares ( ADS ) | |
| Person Discharging Managerial Responsibilities | ||
| Mr Christian Hogg (Executive Director and Chief Executive Officer) | 14,975 | |
| Mr Johnny Cheng (Executive Director and Chief Financial Officer) | 5,857 | |
| Dr Weiguo Su (Executive Director and Chief Scientific Officer) | 10,475 | |
| Total | 31,307 |
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Mr Christian Hogg | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Director and Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hutchison China MediTech Limited | |
| b) | LEI | 2138006X34YDQ6OBYE79 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | ADS each representing five Ordinary Shares of US$0.10 ADS ISIN: US44842L1035 | |
| b) | Nature of the transaction | Vesting of awards granted on March 15, 2017 under Chi-Med's LTIP | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 14,975 ADS | ||
| d) | Aggregated information - Aggregated volume - Price | N/A | |
| e) | Date of the transaction | 2020-03-06 | |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Mr Johnny Cheng | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Director and Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hutchison China MediTech Limited | |
| b) | LEI | 2138006X34YDQ6OBYE79 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | ADS each representing five Ordinary Shares of US$0.10 ADS ISIN: US44842L1035 | |
| b) | Nature of the transaction | Vesting of awards granted on March 15, 2017 under Chi-Med's LTIP | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 5,857 ADS | ||
| d) | Aggregated information - Aggregated volume - Price | N/A | |
| e) | Date of the transaction | 2020-03-06 | |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Dr Weiguo Su | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Director and Chief Scientific Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hutchison China MediTech Limited | |
| b) | LEI | 2138006X34YDQ6OBYE79 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | ADS each representing five Ordinary Shares of US$0.10 ADS ISIN: US44842L1035 | |
| b) | Nature of the transaction | Vesting of awards granted on March 15, 2017 under Chi-Med's LTIP | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 10,475 ADS | ||
| d) | Aggregated information - Aggregated volume - Price | N/A | |
| e) | Date of the transaction | 2020-03-06 | |
| f) | Place of the transaction | Outside a trading venue |
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
| Investor Enquiries | ||
| Mark Lee, Senior Vice President | +852 2121 8200 | |
| Annie Cheng, Vice President | +1 (973) 567 3786 | |
| David Dible, Citigate Dewe Rogerson | +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com | |
| Xuan Yang, Solebury Trout | +1 (415) 971 9412 (Mobile) xyang@troutgroup.com | |
| Media Enquiries | ||
| UK & Europe Anthony Carlisle, Citigate Dewe Rogerson | +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk | |
| Americas Brad Miles, Solebury Trout | +1 (917) 570 7340 (Mobile) bmiles@troutgroup.com | |
| Asia | Joseph Chi Lo, Brunswick | +852 9850 5033 (Mobile) jlo@brunswickgroup.com |
| Zhou Yi, Brunswick | +852 9783 6894 (Mobile) yzhou@brunswickgroup.com | |
| Nominated Advisor | ||
| Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited | +44 (20) 7886 2500 |